 nigrostriatal dopaminergic system vivo positron emission tomography healthy volunteer subjects patients Parkinson disease group healthy control subjects patients Parkinson disease positron emission tomography tracers indicators different specific properties presynaptic dopaminergic system caudate nucleus putamen first tracer -fluorodopa analog levodopa regional brain uptake conversion retention dopamine metabolites second tracer -nomifensine indicator striatal monaminergic reuptake sites dopaminergic tracer dopaminergic nerve terminal density patients Parkinson disease striatal uptake tracers putamen affected caudate Side-to-side differences uptake putamen left-right differences scored clinical motor performance -fluorodopa -nomifensine tracer uptake putamen average normal values substantial part cellular elements dopaminergic nigrostriatal system intact parkinsonian patients contrast extreme depletion endogenous dopamine putamen patients postmortem results support search drug treatments nigrostriatal cell loss disease successful sufficient striatal nerve terminal pool effectiveness levodopa dopamine repletor